Second Remission in Relapsed Childhood Acute Myelogenous Leukemia After Pretreatment with the AML-BFM 83 Protocol
In Germany more than 80% of newly diagnosed children with acute myelogenous leukemia are treated within the cooperative Berlin-Frankfurt-Münster (BFM) studies. Complete remissions (CR) of 80% are achieved with these protocols but one-third of patients relapse within the first 3 years . There are only a few studies on the treatment of relapsed childhood AML; these aim at evaluating new antileukemic drugs for frontline therapy. Most of the studies enrolled either patients with relapsed AML or patients with leukemia refractory to frontline treatment. With various therapeutic regimens complete remission rates of 45%–49% were achieved [2–5]. Except for patients with allogenic bone marrow transplantation, reports on long-time survival are lacking.
KeywordsAcute Myelogenous Leukemia Chemotherapeutic Regimen Complete Remission Rate Late Relapse Central Nervous System Relapse
Unable to display preview. Download preview PDF.
- 2.Mirro J, Crom WR, Kalwinsky DK, Santane VM, Baker DK, Belt J (1990) Targeted plasma drug concentration: a new therapeutic approach to relapsed nonlymphoblastic leukemia in children. Hematology and Blood Transfusion 32: 82–86Google Scholar
- 3.Movassaghi N, Higgins G, Pyesmany A, Baehner R, Chard R, Sather H, Hammond D (1984) Evaluation of Cyclocytidine in reinduction and maintenance therapy of children with acute nonlymphocytic leukemia previously treated with Cytosine Arabinoside: A Report from Children’s Cancer Study Group. Medical and Pediatric Oncology 12: 352–356PubMedCrossRefGoogle Scholar
- 5.Hakami N, Look AT, Steuber PC, Krischer J, Castleberry R, Harris R, Ravindranath Y, Yietti TJ (1987) Combined Etoposide and 5-Azacitidine in children and adolescents with refractory or relapsed acute non lymphocytic leukemia: A Pediatric Oncology Group Study. J Clin Oncol 5: 1022–1025PubMedGoogle Scholar
- 8.Hiddemann W, Martin W-R, Sauerland C-M, Heinecke A, Büchner T (1990) Definition of refractoriness against conventional chemotherapy in acute myeloid Leukemia: A proposal based on the results of retreatment by Thioguanine, Cytosine, Arabinoside and Daunorubicin (TAD 9) in 150 patients with relapse after standardized first line Therapy Leukemia 4(3): 184–188Google Scholar